Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Erol (Ankara, Turkey), A. Bostanoglu (Ankara, Turkey), O. Isik (Ankara, Turkey), K. Turkel (Ankara, Turkey), Z. Oner (Ankara, Turkey), O. Ozdemir Kumbasar (Ankara, Turkey), C. Tulunay Kaya (Ankara, Turkey), T. Sayin (Ankara, Turkey). Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension. 303

Member's Comments

No comment yet.

Related content which might interest you: Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018 The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis. Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018 Year: 2018 Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening Source: Eur Respir Rev 2011; 20: 270-276 Year: 2011 Hemodynamic phenotypes in systemic sclerosis patients screened for pulmonary hypertension – impact of the new PH-definition Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019 Differences between limited and diffuse systemic sclerosis-related pulmonary arterial hypertension Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Lung function and pulmonary hypertension in systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy Source: Eur Respir J 2009; 33: 371-379 Year: 2009 Pulmonary hypertension in systemic sclerosis: different phenotypes Source: Eur Respir Rev, 26 (145) 170056; 10.1183/16000617.0056-2017 Year: 2017 A screening protocol for pulmonary hypertension in systemic sclerosis identifies patients with pulmonary hypertension on exercise Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004 Screening for pulmonary arterial hypertension in systemic sclerosis Source: Eur Respir Rev 2009; 18: 162-169 Year: 2009 Vasodilator testing in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2006; 28: Suppl. 50, 548s Year: 2006 Association of FVC/DLCO with pulmonary hypertension risk and interstitial disease in systemic sclerosis patients Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1701197; 10.1183/13993003.01197-2017 Year: 2018 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018 Predictors of pulmonary artery hypertension in patients with systemic sclerosis Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1800678; 10.1183/13993003.00678-2018 Year: 2018 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020 Year: 2020